Keywords
Last Name
Institution

NORA M NAVONE

TitleProfessor
InstitutionMD Anderson
DepartmentGenitourinary Medical Oncology
Address1515 Holcombe Blvd
Houston TX 77030-4009
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Fong EL, Wan X, Yang J, Morgado M, Mikos AG, Harrington DA, Navone NM, Farach-Carson MC. A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions. Biomaterials. 2016 Jan; 77:164-72. PMID: 26599623.
      View in: PubMed
    2. Liu Z, Xu J, He J, Liu H, Lin P, Wan X, Navone NM, Tong Q, Kwak LW, Orlowski RZ, Yang J. Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget. 2015 Oct 27; 6(33):34329-41. PMID: 26455377.
      View in: PubMed
    3. Labanca E, De Luca P, Gueron G, Paez A, Moiola CP, Massillo C, Porretti J, Giudice J, Zalazar F, Navone N, Vazquez E, De Siervi A. Association of HO-1 and BRCA1 Is Critical for the Maintenance of Cellular Homeostasis in Prostate Cancer. Mol Cancer Res. 2015 Nov; 13(11):1455-64. PMID: 26227317.
      View in: PubMed
    4. Salameh A, Lee AK, Cardó-Vila M, Nunes DN, Efstathiou E, Staquicini FI, Dobroff AS, Marchiò S, Navone NM, Hosoya H, Lauer RC, Wen S, Salmeron CC, Hoang A, Newsham I, Lima LA, Carraro DM, Oliviero S, Kolonin MG, Sidman RL, Do KA, Troncoso P, Logothetis CJ, Brentani RR, Calin GA, Cavenee WK, Dias-Neto E, Pasqualini R, Arap W. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc Natl Acad Sci U S A. 2015 Jul 7; 112(27):8403-8. PMID: 26080435.
      View in: PubMed
    5. Pasqualini R, Millikan RE, Christianson DR, Cardó-Vila M, Driessen WH, Giordano RJ, Hajitou A, Hoang AG, Wen S, Barnhart KF, Baze WB, Marcott VD, Hawke DH, Do KA, Navone NM, Efstathiou E, Troncoso P, Lobb RR, Logothetis CJ, Arap W. Targeting the interleukin-11 receptor ? in metastatic prostate cancer: A first-in-man study. Cancer. 2015 Jul 15; 121(14):2411-21. PMID: 25832466.
      View in: PubMed
    6. Mandelin J, Cardó-Vila M, Driessen WH, Mathew P, Navone NM, Lin SH, Logothetis CJ, Rietz AC, Dobroff AS, Proneth B, Sidman RL, Pasqualini R, Arap W. Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proc Natl Acad Sci U S A. 2015 Mar 24; 112(12):3776-81. PMID: 25762070.
      View in: PubMed
    7. Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Li Ning Tapia EM, Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med. 2014 Sep 3; 6(252):252ra122. PMID: 25186177; PMCID: PMC4407499.
    8. Gueron G, Giudice J, Valacco P, Paez A, Elguero B, Toscani M, Jaworski F, Leskow FC, Cotignola J, Marti M, Binaghi M, Navone N, Vazquez E. Heme-oxygenase-1 implications in cell morphology and the adhesive behavior of prostate cancer cells. Oncotarget. 2014 Jun 30; 5(12):4087-102. PMID: 24961479; PMCID: PMC4147308.
    9. Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal. 2014 May 20; 7(326):ra47. PMID: 24847116.
      View in: PubMed
    10. Fong EL, Martinez M, Yang J, Mikos AG, Navone NM, Harrington DA, Farach-Carson MC. Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening. Mol Pharm. 2014 Jul 7; 11(7):2040-50. PMID: 24779589; PMCID: PMC4096229.
    11. Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. 2014 Mar 15; 74(6):1651-60. PMID: 24473064.
      View in: PubMed
    12. Ferrando M, Wan X, Meiss R, Yang J, De Siervi A, Navone N, Vazquez E. Heme oxygenase-1 (HO-1) expression in prostate cancer cells modulates the oxidative response in bone cells. PLoS One. 2013; 8(11):e80315. PMID: 24224047; PMCID: PMC3817116.
    13. Corn PG, Wang F, McKeehan WL, Navone N. Targeting fibroblast growth factor pathways in prostate cancer. Clin Cancer Res. 2013 Nov 1; 19(21):5856-66. PMID: 24052019; PMCID: PMC3926427.
    14. Cotignola J, Leonardi DB, Shahabi A, Acuña AD, Stern MC, Navone N, Scorticati C, De Siervi A, Mazza O, Vazquez E. Glutathione-S-transferase (GST) polymorphisms are associated with relapse after radical prostatectomy. Prostate Cancer Prostatic Dis. 2013 Mar; 16(1):28-34. PMID: 23146971.
      View in: PubMed
    15. Elguero B, Gueron G, Giudice J, Toscani MA, De Luca P, Zalazar F, Coluccio-Leskow F, Meiss R, Navone N, De Siervi A, Vazquez E. Unveiling the association of STAT3 and HO-1 in prostate cancer: role beyond heme degradation. Neoplasia. 2012 Nov; 14(11):1043-56. PMID: 23226098; PMCID: PMC3514752.
    16. Yang P, Cartwright CA, Li J, Wen S, Prokhorova IN, Shureiqi I, Troncoso P, Navone NM, Newman RA, Kim J. Arachidonic acid metabolism in human prostate cancer. Int J Oncol. 2012 Oct; 41(4):1495-503. PMID: 22895552; PMCID: PMC3982713.
    17. Karlou M, Lu JF, Wu G, Maity S, Tzelepi V, Navone NM, Hoang A, Logothetis CJ, Efstathiou E. Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate. 2012 Nov; 72(15):1638-47. PMID: 22457212.
      View in: PubMed
    18. Yang J, He J, Wang J, Cao Y, Ling J, Qian J, Lu Y, Li H, Zheng Y, Lan Y, Hong S, Matthews J, Starbuck MW, Navone NM, Orlowski RZ, Lin P, Kwak LW, Yi Q. Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia. 2012 Sep; 26(9):2114-23. PMID: 22425892; PMCID: PMC3381862.
    19. Sircar K, Huang H, Hu L, Liu Y, Dhillon J, Cogdell D, Aprikian A, Efstathiou E, Navone N, Troncoso P, Zhang W. Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer. PLoS One. 2012; 7(2):e31259. PMID: 22363599; PMCID: PMC3281954.
    20. Wan X, Liu J, Lu JF, Tzelepi V, Yang J, Starbuck MW, Diao L, Wang J, Efstathiou E, Vazquez ES, Troncoso P, Maity SN, Navone NM. Activation of ?-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res. 2012 Feb 1; 18(3):726-36. PMID: 22298898; PMCID: PMC3271798.
    21. Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Koumakpayi IH, Saad F, Luo D, Bismar TA, Aparicio A, Troncoso P, Navone N, Zhang W. Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. Am J Pathol. 2012 Mar; 180(3):895-903. PMID: 22245216; PMCID: PMC4715215.
    22. Li J, Ding Z, Wang Z, Lu JF, Maity SN, Navone NM, Logothetis CJ, Mills GB, Kim J. Androgen regulation of 5?-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS One. 2011; 6(12):e28840. PMID: 22194926; PMCID: PMC3237548.
    23. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res. 2012 Feb 1; 18(3):666-77. PMID: 22156612; PMCID: PMC3923417.
    24. Wan X, Li ZG, Yingling JM, Yang J, Starbuck MW, Ravoori MK, Kundra V, Vazquez E, Navone NM. Effect of transforming growth factor beta (TGF-?) receptor I kinase inhibitor on prostate cancer bone growth. Bone. 2012 Mar; 50(3):695-703. PMID: 22173053; PMCID: PMC3278589.
    25. Dafni H, Burghardt AJ, Majumdar S, Navone NM, Ronen SM. Vascular patterning and permeability in prostate cancer models with differing osteogenic properties. NMR Biomed. 2012 Jun; 25(6):843-51. PMID: 22134886.
      View in: PubMed
    26. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011 Nov 30; 3(111):111ra121. PMID: 22133722.
      View in: PubMed
    27. Ferrando M, Gueron G, Elguero B, Giudice J, Salles A, Leskow FC, Jares-Erijman EA, Colombo L, Meiss R, Navone N, De Siervi A, Vazquez E. Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer. Angiogenesis. 2011 Dec; 14(4):467-79. PMID: 21833623.
      View in: PubMed
    28. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell. 2011 May 17; 19(5):664-78. PMID: 21575865.
      View in: PubMed
    29. Mohamedali KA, Li ZG, Starbuck MW, Wan X, Yang J, Kim S, Zhang W, Rosenblum MG, Navone NM. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature. Clin Cancer Res. 2011 Apr 15; 17(8):2328-38. PMID: 21343372; PMCID: PMC3078947.
    30. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate. 2011 Jun 1; 71(8):846-56. PMID: 21456067; PMCID: PMC3883511.
    31. Gorlov IP, Sircar K, Zhao H, Maity SN, Navone NM, Gorlova OY, Troncoso P, Pettaway CA, Byun JY, Logothetis CJ. Prioritizing genes associated with prostate cancer development. BMC Cancer. 2010; 10:599. PMID: 21044312; PMCID: PMC2988752.
    32. Prantl L, Muehlberg F, Navone NM, Song YH, Vykoukal J, Logothetis CJ, Alt EU. Adipose tissue-derived stem cells promote prostate tumor growth. Prostate. 2010 Nov 1; 70(15):1709-15. PMID: 20564322.
      View in: PubMed
    33. Guo CC, Dancer JY, Wang Y, Aparicio A, Navone NM, Troncoso P, Czerniak BA. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol. 2011 Jan; 42(1):11-7. PMID: 21040948.
      View in: PubMed
    34. Navone NM. P-TEFb joins the family of cdks in oncology, promotes cell growth of cancer cells. Cell Cycle. 2010 Aug 1; 9(15):2935. PMID: 20703082.
      View in: PubMed
    35. Lee YC, Cheng CJ, Huang M, Bilen MA, Ye X, Navone NM, Chu K, Kao HH, Yu-Lee LY, Wang Z, Lin SH. Androgen depletion up-regulates cadherin-11 expression in prostate cancer. J Pathol. 2010 May; 221(1):68-76. PMID: 20191612; PMCID: PMC2936767.
    36. Ravoori M, Czaplinska AJ, Sikes C, Han L, Johnson EM, Qiao W, Ng C, Cody DD, Murphy WA, Do KA, Navone NM, Kundra V. Quantification of mineralized bone response to prostate cancer by noninvasive in vivo microCT and non-destructive ex vivo microCT and DXA in a mouse model. PLoS One. 2010; 5(3):e9854. PMID: 20360964; PMCID: PMC2847943.
    37. Gueron G, De Siervi A, Ferrando M, Salierno M, De Luca P, Elguero B, Meiss R, Navone N, Vazquez ES. Critical role of endogenous heme oxygenase 1 as a tuner of the invasive potential of prostate cancer cells. Mol Cancer Res. 2009 Nov; 7(11):1745-55. PMID: 19903769.
      View in: PubMed
    38. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest. 2008 Aug; 118(8):2697-710. PMID: 18618013; PMCID: PMC2447924.
    39. Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res. 2008 Jun 15; 14(12):3729-36. PMID: 18559590; PMCID: PMC2562877.
    40. Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene. 2008 Sep 4; 27(39):5195-203. PMID: 18490922; PMCID: PMC2562662.
    41. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL. The current state of preclinical prostate cancer animal models. Prostate. 2008 May 1; 68(6):629-39. PMID: 18213636; PMCID: PMC3681409.
    42. Logothetis CJ, Navone NM, Lin SH. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res. 2008 Mar 15; 14(6):1599-602. PMID: 18347159.
      View in: PubMed
    43. Sacca P, Meiss R, Casas G, Mazza O, Calvo JC, Navone N, Vazquez E. Nuclear translocation of haeme oxygenase-1 is associated to prostate cancer. Br J Cancer. 2007 Dec 17; 97(12):1683-9. PMID: 18026199; PMCID: PMC2360287.
    44. Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, Mathew P, Lopez A, Logothetis CJ, Lin SH, Navone NM. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene. 2008 Jan 24; 27(5):596-603. PMID: 17700537.
      View in: PubMed
    45. Chen N, Ye XC, Chu K, Navone NM, Sage EH, Yu-Lee LY, Logothetis CJ, Lin SH. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res. 2007 Jul 15; 67(14):6544-8. PMID: 17638862; PMCID: PMC2000837.
    46. Cheng CJ, Ye XC, Vakar-Lopez F, Kim J, Tu SM, Chen DT, Navone NM, Yu-Lee LY, Lin SH, Hu MC. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res. 2007 Jul; 5(7):675-84. PMID: 17634423; PMCID: PMC2000833.
    47. Kundra V, Ng CS, Ma J, Bankson JA, Price RE, Cody DD, Do KA, Han L, Navone NM. In vivo imaging of prostate cancer involving bone in a mouse model. Prostate. 2007 Jan 1; 67(1):50-60. PMID: 17031813.
      View in: PubMed
    48. Mohamedali KA, Poblenz AT, Sikes CR, Navone NM, Thorpe PE, Darnay BG, Rosenblum MG. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel. Cancer Res. 2006 Nov 15; 66(22):10919-28. PMID: 17108129.
      View in: PubMed
    49. Peleg S, Khan F, Navone NM, Cody DD, Johnson EM, Van Pelt CS, Posner GH. Inhibition of prostate cancer-meditated osteoblastic bone lesions by the low-calcemic analog 1alpha-hydroxymethyl-16-ene-26,27-bishomo-25-hydroxy vitamin D3. J Steroid Biochem Mol Biol. 2005 Oct; 97(1-2):203-11. PMID: 16081281.
      View in: PubMed
    50. Fizazi K, Navone NM. [Preclinical models of prostate cancer]. Bull Cancer. 2005 Feb; 92(2):129-41. PMID: 15749642.
      View in: PubMed
    51. Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, Navone NM. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res. 2004 Sep-Oct; 24(5A):2897-903. PMID: 15517894.
      View in: PubMed
    52. Navone NM, Olive M, Troncoso P. Isolation and culture of prostate cancer cell lines. Methods Mol Med. 2004; 88:121-32. PMID: 14634223.
      View in: PubMed
    53. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res. 2003 Jul; 9(7):2587-97. PMID: 12855635.
      View in: PubMed
    54. Logothetis C, Tu SM, Navone N. Targeting prostate cancer bone metastases. Cancer. 2003 Feb 1; 97(3 Suppl):785-8. PMID: 12548576.
      View in: PubMed
    55. Martinez LA, Yang J, Vazquez ES, Rodriguez-Vargas Mdel C, Olive M, Hsieh JT, Logothetis CJ, Navone NM. p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis. 2002 Aug; 23(8):1289-96. PMID: 12151346.
      View in: PubMed
    56. Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, Waltenberger J, Thorpe P, Rosenblum MG. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A. 2002 Jun 11; 99(12):7866-71. PMID: 12060733.
      View in: PubMed
    57. Vidanes GM, Paton V, Wallen E, Peehl DM, Navone N, Brooks JD. Silencing of pi-class glutathione S-transferase in MDA PCa 2a and MDA PCa 2b cells. Prostate. 2002 Jun 1; 51(4):225-30. PMID: 11987150.
      View in: PubMed
    58. Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ, Logothetis CJ, Trapman J, Pisters LL, Ordoñez NG, Troncoso P, Navone NM. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res. 2002 Mar; 8(3):775-81. PMID: 11895908.
      View in: PubMed
    59. Plonowski A, Schally AV, Nagy A, Groot K, Krupa M, Navone NM, Logothetis C. Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Cancer Lett. 2002 Feb 8; 176(1):57-63. PMID: 11790454.
      View in: PubMed
    60. Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N, Hsieh JT. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem. 2002 Apr 12; 277(15):12622-31. PMID: 11812785.
      View in: PubMed
    61. Newman RA, Yang J, Raymond M, Finlay V, Cabral F, Vourloumis D, Stephens LC, Troncoso P, Wu X, Logothetis CJ, Nicolaou KC, Navone NM. Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts. Cancer Chemother Pharmacol. 2001 Oct; 48(4):319-26. PMID: 11710633.
      View in: PubMed
    62. Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, Hu M, Olive M, Martinez LA, Wood CG, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res. 2001 Jul 15; 61(14):5652-9. PMID: 11454720.
      View in: PubMed
    63. Zhao XY, Peehl DM, Navone NM, Feldman D. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology. 2000 Jul; 141(7):2548-56. PMID: 10875257.
      View in: PubMed
    64. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med. 2000 Jun; 6(6):703-6. PMID: 10835690.
      View in: PubMed
    65. Navone NM, Rodriquez-Vargas MC, Benedict WF, Troncoso P, McDonnell TJ, Zhou JH, Luthra R, Logothetis CJ. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Clin Cancer Res. 2000 Mar; 6(3):1190-7. PMID: 10741751.
      View in: PubMed
    66. Zhao XY, Boyle B, Krishnan AV, Navone NM, Peehl DM, Feldman D. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol. 1999 Dec; 162(6):2192-9. PMID: 10569618.
      View in: PubMed
    67. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC, Logothetis CJ. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol. 1999 Jan; 161(1):304-8. PMID: 10037428.
      View in: PubMed
    68. Ozen M, Navone NM, Multani AS, Troncoso P, Logothetis CJ, Chung LW, von Eschenbach AC, Pathak S. Structural alterations of chromosome 5 in twelve human prostate cancer cell lines. Cancer Genet Cytogenet. 1998 Oct 15; 106(2):105-9. PMID: 9797773.
      View in: PubMed
    69. Pisters LL, Troncoso P, Navone N. Prolonged survival with metastatic prostate cancer to bone. J Urol. 1998 Jun; 159(6):2100. PMID: 9598540.
      View in: PubMed
    70. Rajagopal S, Navone NM, Troncoso P, Fritsche HA, Chakrabarty S. Modulation of cellular proliferation and production of prostate-specific antigen and matrix adhesion molecules in human prostate carcinoma cells by polypeptide growth factors: comparative analyses of MDA PCa2a with established cell lines. Int J Oncol. 1998 Mar; 12(3):589-95. PMID: 9472097.
      View in: PubMed
    71. Navone NM, Logothetis CJ, von Eschenbach AC, Troncoso P. Model systems of prostate cancer: uses and limitations. Cancer Metastasis Rev. 1998-1999; 17(4):361-71. PMID: 10453280.
      View in: PubMed
    72. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2493-500. PMID: 9815652.
      View in: PubMed
    73. Polo CF, Buzaleh AM, Vazquez ES, Afonso SG, Navone NM, Batlle AM. Griseofulvin-induced hepatopathy due to abnormalities in heme pathway. Gen Pharmacol. 1997 Aug; 29(2):207-10. PMID: 9251900.
      View in: PubMed
    74. McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, Brisbay S, Logothetis CJ. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol. 1997 Feb; 157(2):569-74. PMID: 8996359.
      View in: PubMed
    75. Polo CF, Afonso SG, Navone NM, Rossetti MV, del C Batlle AM. Zinc aminolevulinic acid dehydratase reactivation index as a tool for diagnosis of lead exposure. Ecotoxicol Environ Saf. 1995 Dec; 32(3):267-72. PMID: 8964254.
      View in: PubMed
    76. Chen Y, Navone NM, Conti CJ. Expression of cyclin DI in human prostate cancer cell lines. Urol Oncol. 1995 May-Jun; 1(3):101-8. PMID: 21224101.
      View in: PubMed
    77. Hall MC, Navone NM, Troncoso P, Pollack A, Zagars GK, von Eschenbach AC, Conti CJ, Chung LW. Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology. 1995 Mar; 45(3):470-5. PMID: 7879337.
      View in: PubMed
    78. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst. 1993 Oct 20; 85(20):1657-69. PMID: 7692074.
      View in: PubMed
    79. Navone NM, Vázquez ES, Polo CF, Batlle AM. Rhodanese and ALA-S in mammary tumor and liver from normal and tumor-bearing mice. Comp Biochem Physiol B. 1992 May; 102(1):83-5. PMID: 1526138.
      View in: PubMed
    80. Navone NM, Afonso SG, Polo CF, Batlle AM. Uroporphyrinogen decarboxylase from mouse mammary carcinoma and liver of normal and tumor-bearing mouse. Comp Biochem Physiol B. 1992 May; 102(1):87-92. PMID: 1526139.
      View in: PubMed
    81. Conti CJ, Bianchi AB, Navone NM, Ruggieri BA, Caamano J, Goodrow T, Klein-Szanto AJ. Tumor suppressor genes in squamous cell carcinoma. Prog Clin Biol Res. 1992; 376:85-101. PMID: 1528931.
      View in: PubMed
    82. Navone NM, Bianchi AB, Angel JM, Conti CJ. A novel polymorphism near the mouse Int-2 locus. Mamm Genome. 1992; 3(5):296-7. PMID: 1638089.
      View in: PubMed
    83. Bianchi AB, Navone NM, Aldaz CM, Conti CJ. Overlapping loss of heterozygosity by mitotic recombination on mouse chromosome 7F1-ter in skin carcinogenesis. Proc Natl Acad Sci U S A. 1991 Sep 1; 88(17):7590-4. PMID: 1909026.
      View in: PubMed
    84. Bianchi AB, Navone NM, Conti CJ. Detection of loss of heterozygosity in formalin-fixed paraffin-embedded tumor specimens by the polymerase chain reaction. Am J Pathol. 1991 Feb; 138(2):279-84. PMID: 1992758.
      View in: PubMed
    85. Navone NM, Polo CF, Frisardi AL, Batlle AM. Mouse mammary carcinoma porphobilinogenase and hydroxymethylbilane synthetase. Comp Biochem Physiol B. 1991; 98(1):67-71. PMID: 2060282.
      View in: PubMed
    86. Navone NM, Buzaleh AM, Polo CF, Afonso SG, Vázquez ES, Batlle AM. The effect of griseofulvin on the heme pathway--II. An exhaustive analysis during short and long-term challenge. Gen Pharmacol. 1991; 22(6):1179-83. PMID: 1810812.
      View in: PubMed
    87. Navone NM, Polo CF, Dinger RM, Batlle AM. Heme regulation in mouse mammary carcinoma and liver of tumor bearing mice--I. Effect of allyl-isopropylacetamide and veronal on delta-aminolevulinate synthetase, cytochrome P-450 and cytochrome oxidase. Int J Biochem. 1990; 22(9):1005-8. PMID: 2178097.
      View in: PubMed
    88. Afonso SG, Polo CF, Navone NM, Vazquez ES, Buzaleh AM, Schoua E, Batlle AM. In vivo prevention and reversal by the antimitotic colchicine and other related compounds of some porphyrinogenic drug action on heme pathway. Gen Pharmacol. 1990; 21(4):423-6. PMID: 2379798.
      View in: PubMed
    89. Navone NM, Polo CF, Frisardi AL, Andrade NE, Battle AM. Heme biosynthesis in human breast cancer--mimetic "in vitro" studies and some heme enzymic activity levels. Int J Biochem. 1990; 22(12):1407-11. PMID: 2276414.
      View in: PubMed
    90. Navone NM, Polo CF, Frisardi AL, Batlle AM. Mouse mammary carcinoma delta-aminolevulinate dehydratase. Comp Biochem Physiol B. 1990; 96(4):729-31. PMID: 2225774.
      View in: PubMed
    91. Vazquez E, Afonso S, Buzaleh AM, Navone N, Polo C, Schoua E, Batlle A. The effect of griseofulvin on the heme pathway. Studies on tissue explant cultures. Toxicology. 1987 Oct 12; 46(1):73-82. PMID: 3660422.
      View in: PubMed
    92. Erratum to Mechanistic rationale for inhibition of poly(ADP-Ribose) polymerase in ETS gene fusion-positive prostate cancer [Cancer Cell, 19 (2011) 664-678]. Cancer Cell. 23:557.
    93. Expression of cyclin DI in human prostate cancer cell lines. Urologic Oncology: Seminars and Original Investigations. 1:101-108.
    94. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. Neoplasia (United States). 18:1-9.
    95. A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions. Biomaterials. 77:164-172.
    96. Erratum. Proceedings of the National Academy of Sciences of the United States of America. 99:10941.
    97. BET bromodomain inhibitors enhance efficacy and disrupt resistance to AR antagonists in the treatment of prostate cancer. Molecular Cancer Research. 14:324-331.
    98. Hyperactivated FRS2α-mediated signaling in prostate cancer cells promotes tumor angiogenesis and predicts poor clinical outcome of patients. Oncogene.
    99. Erratum. Science Translational Medicine. 7.
    100. Erratum. Nature Medicine. 6:939.
    101. Targeted molecular-genetic imaging and liganddirected therapy in aggressive variant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 113:12786-12791.
    102. Porphyrin bioasynthesis in human breast cancer. Preliminary mimetic in vitro studies. Medical Science Research. 16:61-62.
    103. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas. Epigenetics. 1-10.
    104. Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget. 6:34329-34341.
    105. Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening. Molecular Pharmaceutics. 11:2040-2050.
    106. About phototoxicity of griseofulvin. Possible mechanisms of action using cultures of tissular explants. Revista Argentina de Dermatologia. 68.
    NAVONE's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description